Created with Highcharts 11.1.0Apr '24Jul '24Oct '24Jan '255.001.635

Profile

Edit
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
URL https://www.geron.com
Investor Relations URL https://ir.geron.com/
HQ State/Province California
Sector Health Care
Industry Biotechnology
Next Earnings Release May. 02, 2025 (est.)
Last Earnings Release Feb. 26, 2025
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Edit
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
URL https://www.geron.com
Investor Relations URL https://ir.geron.com/
HQ State/Province California
Sector Health Care
Industry Biotechnology
Next Earnings Release May. 02, 2025 (est.)
Last Earnings Release Feb. 26, 2025
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A
Quickflows